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Background: The expression of annexin A6 (AnxA6) in AnxA6-deficient non-invasive tumor cells has been shown
to terminate epidermal growth factor receptor (EGFR) activation and downstream signaling. However, as a
scaffolding protein, AnxA6 may stabilize activated cell-surface receptors to promote cellular processes such as tumor
cell motility and invasiveness. In this study, we investigated the contribution of AnxA6 in the activity of EGFR in
invasive breast cancer cells and examined whether the expression status of AnxA6 influences the response of these
cells to EGFR-targeted tyrosine kinase inhibitors (TKIs) and/or patient survival.
Results: We demonstrate that in invasive BT-549 breast cancer cells AnxA6 expression is required for sustained
membrane localization of activated (phosho-Y1068) EGFR and consequently, persistent activation of MAP kinase
ERK1/2 and phosphoinositide 3-kinase/Akt pathways. Depletion of AnxA6 in these cells was accompanied by rapid
degradation of activated EGFR, attenuated downstream signaling and as expected enhanced anchorage-
independent growth. Besides inhibition of cell motility and invasiveness, AnxA6-depleted cells were also more
sensitive to the EGFR-targeted TKIs lapatinib and PD153035. We also provide evidence suggesting that reduced
AnxA6 expression is associated with a better relapse-free survival but poorer distant metastasis-free and overall
survival of basal-like breast cancer patients.
Conclusions: Together this demonstrates that the rapid degradation of activated EGFR in AnxA6-depleted invasive
tumor cells underlies their sensitivity to EGFR-targeted TKIs and reduced motility. These data also suggest that
AnxA6 expression status may be useful for the prediction of the survival and likelihood of basal-like breast cancer
patients to respond to EGFR-targeted therapies.
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Annexin A6 (AnxA6), a structurally unusual member of
the annexin family of calcium-dependent phospholipid
binding proteins, interacts with cellular membranes in a
manner that is distinct from other annexins [1]. AnxA6 has
also been shown to be down regulated in end-stage heart
failure [2], during chronic atrial fibrillation [3] and in* Correspondence: asakwe@mmc.edu
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article, unless otherwise stated.malignant forms of melanomas [4]. We recently also
showed that AnxA6 is down regulated in breast invasive
ductal carcinomas and even more so in breast adenocarcin-
omas [5].The unifying characteristic of these conditions is
that the highly regulated Ca2+ entry into cells is uncoupled
in cells that either lack, or express low levels of AnxA6.
The resulting increase in cytosolic Ca2+ in these cells un-
derlies at least in part, the increased contractility of cardio-
myocytes [6] and enhanced proliferation of tumor cells
[5,7] as well as AnxA6-modulation of tumor cell prolifera-
tion, differentiation and motility. While reduced expressionentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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duced expression of the protein has been shown to be asso-
ciated with a decrease in the migration of invasive breast
cancer cells (BCCs) [5] and chick cranial crest cells [8].
Meanwhile, loss of AnxA6 was associated with a delay in
terminal differentiation of murine growth plate chondro-
cytes due to decreased expression of terminal differenti-
ation markers [9]. This suggests that AnxA6 is a tumor
suppressor and a metastasis promoting factor. However,
available evidence does not suggests a direct involvement of
AnxA6 in these cellular functions. AnxA6 presumably
modulates these cellular functions as a scaffolding protein
by influencing the localization, expression levels and/or ac-
tivity of other cellular factors.
The expression of epidermal growth factor receptor
(EGFR) in basal-like breast cancer is associated with
poor prognosis [10-12] but more importantly, it provides
the possibility to therapeutically target the receptor
using either tyrosine kinase inhibitors (TKIs) or thera-
peutic monoclonal antibodies [13,14]. Although EGFR
levels are elevated in several cancers, its prognostic and
therapeutic significance in various cancers are quite vari-
able. This is presumably due to the association of patient
survival with the total receptor rather than the activated
receptor levels [15]. It is also possible that the relatively
modest EGFR prognostic value in some cancers includ-
ing breast cancer, may be due to the modulation of its
cellular levels and activity by amongst other cellular fac-
tors scaffolding proteins such as MUC4 [16] and AnxA6
[17-20].
AnxA6A is largely considered to be a tumor suppres-
sor. This is based on a number of reports that have
amply demonstrated that over expression of the protein
in the non-invasive A431 epidermoid carcinoma cells as
well as BT20 and MDA-MB-468 breast cancer cells that
either lack, or express low levels of AnxA6 inhibited
their growth [20]. On the other hand, down regulation
of AnxA6 in MDA-MB-436 [20] and BT-549 [5] both of
which express high levels of AnxA6, led to increased
anchorage-independent growth. The inhibition of tumor
cell proliferation following the expression of AnxA6 in
AnxA6-low cells has been shown to be partly due to the
inactivation of activated EGFR and the termination of
EGFR-mediated activation of the Ras pathway. These
studies revealed that the AnxA6-mediated inactivation
of activated EGFR and inhibition of the Ras signaling
pathway were respectively mediated via the interaction
of AnxA6 with activated protein kinase C (PKC)-α [21]
and p120GAP, the Ras-specific guanine nucleotide acti-
vating protein [19,22]. The enhanced growth of AnxA6-
deficient tumor cells on the other hand is currently
believed to be driven by the high cytosolic Ca2+-induced
activation of PKC isoforms that in turn activate the Ras
pathway independently of EGFR activity [20,23]. Besidesthese findings, other reports have suggested that by act-
ing as a link between the actin cytoskeleton and the
plasma and endosomal membranes [7,24,25], its involve-
ment in vesicular transport [26,27] and localization in
cholesterol-rich lipid rafts [28,29], AnxA6 on the con-
trary, contributes to the stabilization of activated recep-
tors on the cell surface [18].
A number of studies have clearly demonstrated that al-
though ligand-activated EGFR is rapidly internalized and
degraded in lysosomes [30-32] it can also be recycled
back to the plasma membrane [32]. Contrary to its in-
hibitory effect on EGFR activation and activity in non-
invasive tumor cells that either lack, or express low
levels of AnxA6 [19,22], we hypothesized that in
AnxA6-expressing invasive tumor cells AnxA6 may pro-
mote a sustained cell-surface expression of activated
EGFR and therefore, persistent receptor activity that
drives cell migration. We therefore, investigated the con-
tribution of AnxA6 in the activity of EGFR in invasive
breast cancer cells and examined whether the expression
status of AnxA6 influences the response of these cells to
EGFR-targeted TKIs and/or patient survival. We demon-
strate that reduced AnxA6 expression not only pro-
moted rapid degradation of activated EGFR and reduced
motility but also sensitized the cells to EGFR-targeted
TKIs. We also show that low AnxA6 expression is asso-
ciated with a better relapse-free survival but poorer
overall and distant metastasis-free survival of basal-like
breast cancer patients. Together, this demonstrates that
the rapid degradation of activated EGFR in AnxA6-
depleted invasive tumor cells underlies their sensitivity
to EGFR-targeted TKIs and attenuated motility. These
data also suggest that AnxA6 expression status may be
useful for the prediction of the survival and likelihood of
basal-like breast cancer patients to respond to EGFR-
targeted therapies.
Results
AnxA6 is required for the localization of activated EGFR
on the surface of breast cancer cells
It has been amply demonstrated that AnxA6 [28,29] and
EGFR [33-35] are components of lipid raft containing
membrane microdomains. It has also been shown that
activation of EGFR is independent of AnxA6 expression
[23], and that intact lipid rafts were required for the acti-
vation of the receptor [35]. Together, this led us to
speculate that AnxA6 expression is required for sus-
tained cell surface localization of activated EGFR in
BCCs. To test this we first sought to compare the activa-
tion and activity of EGFR in the invasive AnxA6 high
BT-549 cells with that of the non-invasive AnxA6-low
HCC1806 as well as MDA-MB-468 cells (with amplified
EGFR expression). We show that the expression of
AnxA6 is barely detectable in HCC1806 and MDA-MB-
Koumangoye et al. Molecular Cancer 2013, 12:167 Page 3 of 14
http://www.molecular-cancer.com/content/12/1/167468 cells compared to BT-549 cells (Figure 1A). Mean-
while, BT-549 and HCC1806 expressed relatively similar
levels of total EGFR while the expression of EGFR was
at least 3-fold higher in MDA-MB-468 (Figure 1A and
B). Interestingly, treatment of these cells with EGFFigure 1 AnxA6 is required for the localization of activated EGFR on t
468 cells were grown to 70% confluency, followed by serum starvation for
scrapping in ice-cold PBS. Equal amounts of whole cell lysates were separa
lyzed by Western blotting with the indicated antibodies. B) Densitometric
BT-549 cells from at least three independent experiments. C) Densitometric
EGFR (p-Y1068) relative to untreated control cells from at least three indep
surface localization of activated EGFR in breast cancer cells. BT-549, HCC180
DMEM/F12 medium, then serum-starved overnight. The cells were subsequ
treated with or without EGF for 5 min. The cells were then fixed for 20 min
munofluorescence staining with antibodies to phospho-EGFR (Y1068) andstimulated to varying extents, the autophosphorylation
of the receptor on Y1068 (p-EGFR Y1068). Analysis of
the time course for the activation of EGFR revealed that
the receptor remained strongly activated even after
90 min in MDA-MB-468 cells. The activated receptorhe surface of breast cancer cells. A) BT-549, HCC1806 and MDA-MB-
24 h. Cells were then treated with EGF for 0–90 min and harvested by
ted in 4-12% polyacrylamide gels under reducing conditions and ana-
analysis of EGFR expression. Bars represent EGFR expression relative to
analysis of EGF-induced EGFR activation. Points represent activated
endent experiments. D) AnxA6 expression promotes a sustained cell
6 and MDA-MB-468 cells were grown on glass cover slips in complete
ently washed twice in Hanks’ balanced salt solution (HBSS) and then
in 3% paraformaldehyde in PBS. Activated EGFR was detected by im-
counterstained with DAPI. Bars = 10 μm.
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and BT-549 cells (Figure 1C). Figure 1A also shows that
in the AnxA6-high BT-549 cells, the activation of EGFR
led to a sustained activation of MAP kinase ERK1/2 (p-
ERK1/2). Paradoxically, in the AnxA6-low HCC1806
and MDA-MB-468 cells and compared to BT-549 cells,
EGFR activation led to relatively reduced activation of
ERK1/2 (Figure 1A).
To explain this paradox, we examined the localization
of the activated receptor in the three cell lines by im-
munofluorescence. As shown in Figure 1D, there was a
robust EGF-stimulated activation of EGFR in the
AnxA6-low MDA-MB-468 cells. Interestingly, the acti-
vated EGFR in these cells was essentially localized to the
perinuclear/cytoplasmic regions (red arrow heads) and
in some cells, sequestered into the nucleus (white arrow
head). Similarly, and consistent with Figure 1A, in the
AnxA6-low HCC1806 cells, plasma membrane-localized
activated EGFR (red arrow head) was also barely detect-
able (Figure 1D). On the contrary, in the AnxA6-high
BT-549 cells, the activated EGFR was predominantly lo-
calized to the plasma membrane (red arrow heads).
These data suggest that AnxA6 enhances the localization
of activated EGFR on the cell surface and that this is ac-
companied by sustained activation of down-stream effec-
tors such as ERK1/2.
To further ascertain the requirement of AnxA6 in the
sustained localization of activated EGFR at the cell surface,
and whether this is required for the invasiveness of these
cells, we used RNA interference to down-regulate AnxA6
in the AnxA6-high BT-549 cells. Two AnxA6-depleted cell
lines designated BT-A6sh2 (clone A1) and BT-A6sh5 (clone
A3) were selected from 10 different clones (Additional
file 1: Figure S1) and respectively showed ~30% and >80%
AnxA6 depletion by Western blotting (Figure 2A). The
AnxA6-depleted cells grew more efficiently than the con-
trol cells (Figure 2B) and as previously shown [5], their mo-
tility was significantly inhibited (Figure 2C). As shown in
Figure 2D AnxA6 depletion also induced a transformation
from invasive stellate colony morphology with long in-
vasive projections in control BT-549 cells to the non-
invasive acinar-like colony morphology in BT-A6sh5 cells.
Invasive projections in BT-A6sh5 cells if discernible were
much shorter than those in control cells, suggesting loss of
invasiveness. This change in colony morphology is
dependent on AnxA6 expression level because BT-A6sh2
cells showed intermediate colony morphologies. Based on
these data, the BT-A6sh5 cell line with the most AnxA6 de-
pletion was used as the AnxA6-depleted cell line in most of
the following experiments. Interestingly, a similar extent of
AnxA6 down regulation in MDA-MB-231 cells did not
substantially lead to altered colony morphology and if any-
thing, the cells tended to be more motile than the control
cells (Figure 2E-H).To substantiate the different outcomes of AnxA6 de-
pletion in BT-549 and MDA-MB-231 TNBC cell lines
on cell growth and motility, we examined the expression
of AnxA6 and EGFR genes in these and other breast cell
lines by qRT-PCR. This analysis revealed that MDA-
MB-231 cells express relatively reduced levels of both
AnxA6 and EGFR compared to BT-549 cells (Additional
file 2: Figure S2A and B). We also demonstrate that the
response of MDA-MB-231 to EGF treatment is also dif-
ferent from that in BT-549 cells in that while PI3 kinase/
Akt and MAP kinase ERK1/2 are strongly activated in
BT-549 cells, Akt and to a lesser extent ERK1/2 activa-
tion in MDA-MB-231 cells are relatively attenuated
(Additional file 2: Figure S2B). As previously reported in
other AnxA6-deficient tumor cells [20], over expression
of AnxA6 in HCC1806 cells on the other hand was asso-
ciated with reduced activation of the receptor and
ERK1/2 (Additional file 3: Figure S3A-D). AnxA6 ex-
pression in HCC1806 cells also inhibited their growth in
3D cultures (Additional file 3: Figure S3E). These data
suggest that in triple negative breast cancer cells, the
modulation of EGFR activation and/or activity by AnxA6
is not only dependent on the AnxA6 expression levels
but is also cell type specific.
Reduced AnxA6 expression promotes the degradation of
Activated EGFR
The desensitization of ligand activated EGFR like most
cell surface receptors predominantly occur by rapid in-
ternalization of receptor-ligand complexes and degrad-
ation in lysosomes. Given the strong cell surface
expression of activated EGFR in AnxA6 expressing BT-
549 cells, we speculated that the virtually absent expres-
sion and attenuated activity of the receptor in the
AnxA6-low HCC1806 and MDA-MB-468 cells could be
attributed to the fate of the activated receptor. To verify
this, BT-549 control or AnxA6-depleted cells were
treated with or without EGF for 0–90 min, surface bio-
tinylated and the fate of EGFR examined by western
blotting. Assessment of the residual levels of biotinylated
surface-associated total and pY1068-EGFR in control
(AnxA6-high) and AnxA6-depleted (AnxA6-low) BT-
549 cells revealed that EGFR activation per se was
indeed unaffected by AnxA6 depletion (Figure 3A). As
expected, the levels of remaining ligand-activated EGFR
decreased with time in both cell lines. However, the re-
sidual cell surface-associated activated EGFR decreased
more rapidly in AnxA6-depleted cells (BT-A6sh5) com-
pared to that in control cells (Figure 3A and B). By
90 min 60% of the activated EGFR in control cells was
still cell surface-associated compared to only 20% in
AnxA6-depleted cells. Similarly, the decrease in total cell
surface (biotinylated) EGFR in the control cells was ini-
tially more rapid but this continued more slowly
Figure 2 Depletion of AnxA6 in invasive breast cancer cells promotes cell proliferation but inhibits cell motility. (A) AnxA6-depleted BT-
549 cell lines were generated as described in “Materials and methods”. Whole cell lysates from the selected clones designated A6sh2 and A6sh5,
were analyzed by Western blotting. (B) Cell proliferation assays. Cells were plated in quadruplicate in 24 well plates and cultured for 72 h in
complete DMEM/F12 medium. Cell growth and viability was assayed using PrestoBlue reagent. Bars represent cell growth ± S.E.M from three inde-
pendent determinations. * p < 0.05; *** p < 0.001. (C) Migration assays. Serum-starved AnxA6-depleted BT-549 and control cells were plated in du-
plicate in the upper chambers of 8 μm culture inserts. Complete DMEM/F12 was used as the chemoattractant. Bars represent the number of
migrated cells/field ± s.d from three independent determinations. * p < 0.001. (D) Anchorage-independent growth of AnxA6-depleted BT-549 cells.
Control (BT-EV) and AnxA6-depleted (BT-A6sh5 and BT-A6sh2) cells were maintained in matrigel 3D cultures for up to 10 days. Digital images of
the colonies were captured with a digital camera (x10 magnification). (E-H) Analyses of AnxA6-depleted MDA-MB-231 cells. The expression levels
of AnxA6 (E), Densitometric analysis of AnxA6 expression (F), cell migration (G) and growth in 3D cultures (H) were examined as described in
A-D above.
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in the down-regulation of biotin-labeled EGFR that was
followed by a more rapid decrease in the cell surface
EGFR levels (Figure 3A and C). Within 90 min of EGF
treatment, the receptor in AnxA6-depleted cells de-
creased to about 10% compared to about 40% in control
cells. Taken together and consistent with data inFigure 1D, these data reveal that AnxA6 depletion in in-
vasive breast cancer cells was accompanied by a rapid
decrease in the total and activated cell surface EGFR
levels. Furthermore, the transient delay in AnxA6-
depleted cells versus a rapid initial decrease in the levels
in control cells suggests a role of AnxA6 in the internal-
ization and/or trafficking of the activated receptor.
Figure 3 Down regulation of AnxA6 in invasive breast cancer cells enhances the degradation of cell surface-associated EGFR. (A) AnxA6
depleted (BT-A6sh5) and control (BT-EV) cells were treated with EGF for 0–90 min and the cell surface-associated proteins were biotinylated as de-
scribed in “materials and methods”. The biotinylated proteins were isolated from whole cell lysates using Streptavidin-agarose beads and analyzed
by Western blotting using antibodies to activated and total EGFR. Ponceau S staining of the blots was used as loading control. (B and C) Densito-
metric analysis of residual cell surface-associated activated EGFR (B) and cell surface-associated total EGFR (C). Points represent residual biotin-
labeled cell surface-associated EGFR in the control (solid lines with closed circles) and AnxA6-depleted cells (broken lines with open circles) at the
indicated times from a representative experiment. IP = immunoprecipitation; WB = western blot.
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in the activated cell surface EGFR in AnxA6-depleted cells
and/or the relatively minimal activation of ERK1/2 in either
HCC1806 or MDA-MB-468 cells could also be attributed
to the lack of or relatively low levels of AnxA6. To do this
we examined the residual levels of total EGFR in the
AnxA6-depleted and control BT-549 cells. This analysis re-
vealed that the EGF-activated (Figure 4A and B) and the
total cellular receptor levels (Figure 4A and C) in control
cells remained relatively constant while the receptor levels
in AnxA6-depleted cells were not only lower (by at least 3-
fold after 90 min), but also decreased more rapidly with
time. Densitometric analysis of EGF-stimulated activation
of ERK1/2 (Figure 4D) and Akt (Figure 4E) also reveal that
these downstream targets were strongly inhibited in the
AnxA6-depleted BT-549 cells compared to control cells.
Together with data in Figure 3, this suggests that AnxA6 is
necessary for the stabilization of the receptor on the cell
surface and correspondingly, sustained signaling to down-
stream effectors (ERK1/2 and Akt).
To demonstrate that reduced AnxA6 expression en-
hanced EGFR degradation, control and AnxA6-depleted
BT-549 cells were serum-starved overnight in the presence
or absence of chloroquine (CLQ). The cells were thentreated with or without EGF and the residual total and acti-
vated EGFR were examined by western blotting. As shown
in Figure 5A-D, although CLQ treatment did not abolish
the degradation of the activated receptor, the total cellular
levels of receptor in the control and AnxA6-depleted BT-
549 cells were stabilized by CLQ treatment. Interestingly,
the levels of the receptor (t-EGFR) in AnxA6-depleted cells
were restored to those in the control cell by 90 min
(Figure 5A and C). To verify whether there were discernible
differences in the degradation and recycling of the activated
receptor in the control and AnxA6-depleted BT-549 cells,
we examined the co-localization of EGF-activated EGFR
with either LAMP1 (a late endosomal marker) or Rab11 (a
recycling endosomal marker). As depicted in Figure 5E,
within 5 min of EGF treatment, cell surface activated EGFR
was clearly discernible in the control cells but the cell sur-
face expression was lost by 90 min (arrows). On the con-
trary, even within 5 min of EGF treatment, most of the
activated EGFR was intracellular in AnxA6-depleted cells
(Figure 5E, arrows). We also observed a greater extent of
co-localization of activated EGFR with LAMP1 in the
AnxA6-depleted BT-549 cells compared to the control
cells. Meanwhile, the activated receptor co-localized with
Rab11 in both the control and AnxA6-depeleted cells.
Figure 4 Effects of AnxA6-depletion on the dynamics of total cellular EGFR. A) AnxA6-depleted (BT-A6sh5) and control (BT-EV) BT-549 cells
were treated with EGF for 0–90 min and whole cell lysates were analyzed by Western blotting to determine the residual activated and total EGFR.
(B-E) Densitometric analysis of residual activated EGFR (B), total EGFR (C) phospho-ERK1/2 (D) and phospho-Akt (E) in BT-EV (solid lines with dark
circles) and BT-A6sh5 (broken lines with open circles). Points represent whole cellular EGFR/activated EGFR remaining at the indicated times or ac-
tivated ERk1/2 and Akt in the control cells (closed circles) and AnxA6-depleted cells (open circles) from a representative experiment.
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recycled in these cells and that EGFR degradation is en-
hanced in the AnxA6-depeleted cells.
AnxA6-depleted invasive breast cancer cells are sensitive
to EGFR tyrosine kinase inhibitors
Given that down regulation of AnxA6 in invasive breast
cancer cells was accompanied by a decrease in the total
and activated EGFR in invasive breast cancer cells, we
speculated that AnxA6-depletion in these cells might
affect their response to EGFR-targeted TKIs. To explore
this further, AnxA6-depleted and control BT-549 cells
were treated with various concentrations (0–10 μM) of
EGFR-targeted TKIs for 72 h. Figure 6A shows that gefi-
tinib (Iressa) was the least potent of the four compounds
while canertinib (CI-1033) was the most potent. In a
concentration-dependent manner, AnxA6-depleted BT-
549 cells were more sensitive to lapatinib (Tykerb) and
PD153035 (Tyrphostin, AG 1517) compared to controlcells. As shown in Table 1, the IC50s for inhibition of
cell growth for lapatinib and PD153035 were signifi-
cantly lower in AnxA6-depleted cells compared to con-
trol cells. This suggests that reduced AnxA6 sensitizes
invasive BCCs to some EGFR-targeted TKIs.
To validate the above data, we compared the response
to these compounds of AnxA6-depleted MDA-MB-231
and BT-549 cells as well as AnxA6-over expressing
HCC1806 cells with their respective controls. As
depicted in Figure 6B, treatment of these cells with these
compounds (5 μM) or DMSO control confirmed that
while AnxA6 depletion in the invasive BT-549 cells sig-
nificantly sensitized the cells to lapatinib, PD153035 and
canertinib, AnxA6-depletion in MDA-MB-231 cells did
not significantly alter their sensitivity to these com-
pounds. Meanwhile, over expression of AnxA6 in
HCC1806 did not alter their response to these EGFR-
targeted TKIs. Together these data confirm the variable
response of breast cancer cells to EGFR targeted
Figure 5 Effects of AnxA6-depletion on lysosomal degradation and recycling of EGFR. A-D) Control BT-EV (A and B) or AnxA6-depleted
BT-A6sh5 (C and D) cells were pretreated overnight with or without CLQ (50 μg/ml) during serum-starvation. Cells were briefly rinsed in HBSS,
treated with EGF for up to 90 min in the presence or absence of CLQ respectively. Total and Y1068-EGFR were examined by western blotting.
E) Serum-starved AnxA6-depleted (BT-A6sh5) and control (BT-EV) cells grown on glass cover slips were treated with EGF for 5 or 90 min. The cells
were fixed in 3.7% PBS-buffered formaldehyde and processed for indirect immunofluorescence as described in Figure 1D using anti-pY1068 EGFR
(green) and either LAMP1 or Rab11 (red). Nuclei were stained with DAPI.
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be more relevant in breast cancer subtypes such as
EGFR expressing invasive basal-like breast cancer.
AnxA6 expression status is associated with the survival of
patients with basal-like breast cancer
To support the above conclusion, we examined whether
AnxA6 expression status also influences the survival of
breast cancer patients with varied clinical disease. To do
this we used the KM plotter, a recently reported publicly
available online survival analysis tool [36] that has been
used extensively to analyze the expression of 22,277
genes on the survival of 2,977 breast cancer patients
[37-39]. This analysis revealed that, AnxA6 expressionstatus is not associated with the overall (OS), relapse-
free (RFS) or distant metastasis-free (DMFS) survival of
all breast cancer patients combined (Figure 7A). AnxA6
expression status also is not associated with the survival
of patients with luminal breast cancer or those with dif-
ferent HER2, estrogen or progesterone receptor status.
However, AnxA6 expression status is significantly associ-
ated with the survival of patients with basal-like breast
cancer. As shown in Figure 7B, low AnxA6 expression is
associated with a significantly higher RFS for patients
with basal-like breast cancer (p = 0.023). High AnxA6
levels were on the other hand, are associated with higher
OS (p = 0.0024) and DMFS (p = 0.019) for patients with
this breast cancer subtype. A previous evaluation of
Figure 6 Down regulation of AnxA6 sensitizes invasive breast cancer cells to EGFR-targeted TKIs. A) Control (BT-EV) and AnxA6-depleted
(A6sh5) BT-549 cells were cultured as above and treated with the indicated concentrations of the indicated EGFR TKIs for 72 h. Cell viability/prolif-
eration was determined using PrestoBlue cell viability assay. Experiments were performed in triplicate and repeated at least three times. Points
represent mean viability ± S.E.M relative to DMSO control treated cells. * p < 0.05, *** p < 0.0001 versus respective controls. B) AnxA6-depleted
MDA-MB-231 and BT-549 as well as AnxA6-over expressing HCC1806 cells with their respective controls were treated with 5 μM of the indicated
EGFR-TKI or DMSO control. Cell viability was determined as above. Bars represent mean viability ± S.E.M relative to DMSO control treated cells.
* p < 0.05 versus respective controls.
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showed that high EGFR expression is associated with
lower RFS for patients with head and neck, ovarian, cer-
vical, bladder and oesophageal cancers [15]. However,
the prognostic value of EGFR expression in other can-
cers including breast cancer was found to be modest
[15].
Discussion
Two opposing notions have thus far emerged from sev-
eral studies on the potential functions of AnxA6 in can-
cer progression. On one hand, AnxA6 has been shown
to terminate EGFR activity by not only inhibiting theactivation of the receptor but also by inhibiting EGFR-
induced activation of the Ras pathway [20,23]. This is
supported by the inhibition of anchorage-independent
growth following over expression of AnxA6 in cells that
either lack, or express low levels of the protein [20,23].
On the contrary, there is ample evidence suggesting that
AnxA6 contributes to the stabilization of activated re-
ceptors on biological membranes that eventually leads to
sustained downstream signaling. However, the involve-
ment if any, of AnxA6 in the stabilization of EGFR on
the cell surface is as yet unclear. In the present study we
showed that AnxA6 is indeed required for the sustained
localization of activated EGFR on the surface of invasive
Table 1 IC50 values for EGFR-targeted TKIs in control and AnxA6-depleted invasive breast cancer cells
EGFR-targeted TKI BT-549-EV BT-549-A6sh Fold change EV:A6sh P-value EV:A6sh
PD153035 6.46 ± 0.62 4.16 ± 0.12 1.55 0.02*
Lapatinib 14.09 ± 1.75 5.99 ± 1.77 2.35 0.03*
Canertinib 4.30 ± 0.24 3.96 ± 0.11 1.09 0.10
Gefitinib 14.43 ± 0.71 13.51 ± 2.83 1.07 0.80
IC50 - half maximal inhibitory concentration (μM) estimated from the regression plots for the indicated tyrosine kinase inhibitors (TKI). BT-549-EV, control BT-549
cells; BT-549-A6sh, AnxA6-depleted BT-549 cells. For fold change and p-values, EV: A6sh denotes, BT-549 control cells versus AnxA6-depleted cells. *Statistically sig-
nificant at p < 0.05.
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tion of downstream effectors that drive motility and in-
vasiveness of the cells. This notion is supported by the
rapid degradation of activated EGFR, loss of invasiveness
and sensitivity to EGFR-targeted TKIs following down
regulation of AnxA6 in invasive breast cancer cells.
Meanwhile the enhanced proliferation of cells that lack
or express low levels of AnxA6 has been shown to be
mediated by PKC activation of the Ras pathway inde-
pendently of EGFR activity [20,23]. Together, these dataFigure 7 Survival analyses of patients with high and low AnxA6-expr
between high or low AnxA6 expression and recurrence-free (RFS), distant m
patients combined and (B) basal-like breast cancer patients. The Kaplan-Me
dicated for low AnxA6 expression status (black) and for high AnxA6 expressuggest that while stabilization of activated EGFR by
AnxA6 may be important in the dissemination of inva-
sive tumor cells, EGFR activity is dispensable in the en-
hanced proliferation of cells that either lack, or express
low levels of AnxA6. Conflicting data were however, ob-
served following down regulation of AnxA6 in the
AnxA6-high BT-549 cells and in MDA-MB-231 cells
that expressed comparatively lower levels of the proteins.
Given the heterogeneity of breast cancer cells, it is
plausible to suggest that the different outcomes ofessing breast cancers. Kaplan Meier plots showing the relationship
etastasis-free (DMFS) and overall survival (OS) of (A) all breast cancer
ier plots and the number of patients at risk at given time points are in-
sion status (red).
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BT-549 cells are cell type specific and presumably dic-
tated by the level of AnxA6 expression.
It is well established that activated EGFR is endocy-
tosed and either degraded in lysosomes or recycled back
to the cell surface [30,32,40]. It has also been shown that
receptors localized at the cell surface are more efficient
in eliciting downstream signaling than those localized in
endocytic compartments [41,42]. The strong activation
of EGFR in the AnxA6-low MDA-MB-468 cells with
relatively reduced activation of ERK1/2 is consistent with
the localization of activated EGFR in the perinuclear/
endocytic compartment as opposed to plasma mem-
brane localized activated EGFR. The plasma membrane
localization of activated receptor correlates with robust
activation of ERK1/2 in the AnxA6-high BT-549 cells.
From previous studies that demonstrated that both
EGFR [33,35,43] and AnxA6 [17,44,45] are components
of lipid rafts and that EGFR activation occurs in lipid
rafts [35], it appears that the AnxA6-dependent mem-
brane stabilization of activated EGFR occurs mainly in
lipid rafts. Therefore, the low levels of activated EGFR
on the surface of MDA-MB-468 or HCC1806 cells and
the reduced levels of activated receptor in AnxA6-
depleted BT-549 cells may be attributed to the absence
or disruption of AnxA6-stabilized lipid rafts in these
cells.
The development of resistance to TKIs is common
and represents a major impediment to targeted treat-
ments with these compounds. A recent study demon-
strated that localization of EGFR in lipid rafts enhanced
the resistance of tumor cells to gefitinib [33]. Consistent
with this report, we also showed that AnxA6-depleted
BT-549 cells were more sensitive to lapatinib and
PD153035 EGFR-targeted TKIs. This increase in the re-
sponse of AnxA6-depleted cells to EGFR-targeted TKIs
may be attributed to the disruption of AnxA6-stabilized
lipid rafts and the accompanying instability of activated
EGFR. Although further studies are warranted, AnxA6
expression status may underlie a novel mechanism for
the development of resistance to EGFR-targeted therap-
ies. Pending validation, patients with the more aggressive
basal-like breast cancers in which AnxA6 expression is
low may be more likely to respond to some EGFR-
targeted therapies.
The growing evidence that AnxA6 expression pro-
motes cell migration but attenuates cell proliferation
[5,7] implies that this tumor suppressor plays an import-
ant role in breast cancer progression and/or patient sur-
vival. This also suggests that AnxA6 expression is
associated with cell motility while reduced AnxA6 ex-
pression is associated with enhanced tumor cell growth.
Given that AnxA6 expression is lower in breast cancer,
it was necessary to assess whether AnxA6 expressionstatus is associated with patient outcome. We provide
evidence suggesting that reduced AnxA6 expression is
significantly associated with higher recurrence-free but
lower distant metastasis-free (DMFS) and overall sur-
vival of patients with basal-like breast cancer. Basal-like
breast cancers are highly aggressive cancers with early
patterns of relapse and metastasis to visceral organs
[46]. The association of AnxA6 expression status with
the survival of patients with this breast cancer subtype is
consistent with the modulation of the stability of acti-
vated EGFR in invasive breast cancer cells by AnxA6.
Analysis of more than 200 studies involving more than
20,000 patients revealed that the expression of EGFR
was also associated with reduced recurrence-free sur-
vival in patients with head and neck, ovarian, cervical,
bladder and oesophageal cancers. However, EGFR ex-
pression was found to exert only a modest prognostic
value in other cancers including breast cancer [15]. The
low prognostic value was suggested to be due to the cor-
relation of patient survival with the total rather than the
activated receptor [15]. It is also possible that this is due
to the fact that EGFR activation and activity are modu-
lated by other cellular factors including scaffolding pro-
teins such as MUC4 [16] and AnxA6 [17-20]. The
poorer distant metastasis-free and overall survival of pa-
tients with low AnxA6-expressing basal-like breast can-
cers could be attributed to the potentially more
aggressive growth of the tumors and/or secondary le-
sions. On the other hand, and as demonstrated in this
study, the better recurrence-free survival of low AnxA6-
expressing basal-like breast cancer patients may be due
to the their greater probability to respond to targeted
therapy.
Conclusions
In summary, our study is the first to describe an associ-
ation between a member of the calcium-dependent
membrane binding annexin family and survival of pa-
tients affected by the highly aggressive basal-like breast
cancer. This study demonstrates that the enhanced deg-
radation of activated EGFR in AnxA6-depleted invasive
breast cancer cells underlies their sensitivity to EGFR-
targeted TKIs and attenuated motility. Further studies
are warranted to provide a rationale for the use of
AnxA6 expression status as a predictive marker for
basal-like breast cancer and to identify patients with this
breast cancer subtype who are more likely to respond to
EGFR-targeted therapies.
Methods
Cell lines and cell culture
The following breast cancer cell lines BT-549, MDA-MB-
231 (MDA-MB-231), HCC1806 were purchased from
American Type Culture Collection (ATCC). MDA-MB-468
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mond, Vanderbilt Medical Center (Nashville, TN). These cell
lines were cultured in DMEM/F12 containing 10% FBS,
penicillin (100 units/ml), and streptomycin (50 units/ml).
Cells were maintained at 37°C in a humidified CO2 incuba-
tor. Where indicated, serum-starvation of cells was achieved
by culturing the cells in DMEM/F12 containing 0.5% FBS
for 24 to 48 h.
Antibodies and other reagents
Antibodies against EGFR, phospho-EGFR (pY1068),
phospho-extracellular signal-regulated kinase 1/2 (pERK1/
2, T202/Y204) and phospho-Akt (pS473) were purchased
from Cell Signaling Technology (Beverly, MA, USA). Anti-
bodies against ERK2, Akt1, GAPDH and AnxA6 were pur-
chased from Santa Cruz Biotechnology, Inc. Antibodies
specific for the flag-epitope (anti-flag M2), β-tubulin and β-
actin were obtained from Sigma. Except otherwise indi-
cated, secondary anti-mouse, anti-goat and anti-rabbit
horseradish peroxidase-conjugated antibodies were pur-
chased from Santa Cruz Biotechnology, Inc or Sigma.
EGFR Tyrosine Kinase Inhibitor Set including canertinib,
erlotinib hydrochloride, gefitinib, lapatinib ditosylate and
PD153035 hydrochloride was purchased from BioVision
Inc. Sulfo-NHS-biotin and protease inhibitor cocktail were
products from Sigma.
Plasmid constructs and transfections
Small hairpin RNAs (shRNAs) targeting the coding
sequence of AnxA6 in pGIPZ lentiviral vector, a non-
silencing shRNA control or the empty vector (Open
Biosystems Inc.), were used to transfect BT-549 and
MDA-MB-231 BCCs using Lipofectamine 2000 (Invi-
trogen). The cells were selected with puromycin 48 h
post-transfection for up to three weeks. Cells express-
ing high levels of GFP were then sorted by flow cy-
tometry, cloned by limiting dilution, and the isolated
clones were expanded in selection medium containing
puromycin (2 μg /ml). The following shRNA se-
quences were used to target AnxA6 in BT-549 and
MDA-MB-231 cells: A6sh2, 5'- TTCAGCATTGGTC
CGAGTG-3'; A6sh5, 5'-TGTGTCTTCGTCAGTCCC
G-3'. For experiments involving over expression of
AnxA6, the coding sequence of AnxA6 variant 1 (ac-
cession No. NM_001155.4) was amplified from plas-
mid pCMV-Sport6-AnxA6 (Open Biosystems Inc.).
The fragment was cloned into Hind III and Xho I lin-
earized pCMV-3Tag-8 (Clontech), and the construct
used to transfect the AnxA6-low HCC1806 BCCs
using Fugene6 transfection reagent (Promega). The
transfected cells herein designated 1806-Anx6 and
1806-EV were selected with hygromycin, cloned
as above and expanded in continued hygromycin
(100 μg/ml) selection.Immunofluorescence microscopy
Cells were plated sparsely on glass cover slips and allowed
to grow until they formed colonies of a few cells. Cells were
then serum-starved overnight and treated with or without
EGF for 5 min. Indirect immunofluorescence staining was
performed as previously described [5] using pEGFR
(Y1068) antibodies and FITC-conjugated secondary anti-
bodies. Cover-slips were mounted with ProLong Gold anti-
fade containing DAPI (Invitrogen). Images were captured
using a Nikon A1R confocal microscope with 60× oil-
immersion objectives and analyzed using the NIS software.Cell-surface biotinylation and Western blotting
Cells were grown in complete medium until they
were 70% confluent, then serum-starved for 24 h and
treated with or without EGF for the indicated time
points. Following treatment, cells were washed twice
with ice-cold phosphate-buffered saline (PBS) pH 7.4,
with 0.5 mM Ca2+ and 1 mM Mg2+) and then incu-
bated with Sulfo-NHS-biotin (0.2 mg/ml in cold PBS)
for 30 min at 4°C. Unreacted biotin was quenched
with ice-cold 100 mM glycine in PBS for 15 min at
4°C. Whole cell extracts were prepared in TNE lysis
buffer (150 mm NaCl, 10 mm Tris–HCl pH 8.0,
1 mm EDTA, and 1% Nonidet P-40 with protease
and phosphatase inhibitors). Biotinylated (cell surface)
proteins isolated using Streptavidin-agarose beads and
whole cell extracts were used for the detection of cell
surface and total cellular EGFR respectively by West-
ern blotting as previously described [5]. Immuno-
reactive bands were visualized by enhanced chemilu-
minescence (ECL; Pierce) and quantified using NIH
Image J software.Activation of EGFR and downstream signaling assays
Breast epithelial and BCCs were cultured until they were
70% confluent then serum-starved overnight and treated
with 50 ng/ml EGF (EMD Biosciences) in Hank’s bal-
anced salt solution (HBSS) for the indicated time pe-
riods. The EGF treated cells were scraped in ice-cold
PBS and total cell lysates prepared as described previ-
ously [5]. EGFR activation was detected by immunoblot-
ting with anti-EGFR (pY1068) and antibodies to total
EGFR. Activation of downstream signaling cascades was
determined by Western blotting using ant-pErk1/2
(pT202/pY204) and anti-pAkt (S473). Immunoblotting
with antibodies to either anti-Erk2, anti GAPDH or anti-
β-tubulin were used as the loading controls. Immuno-
reactive bands were revealed by ECL, scanned and quan-
tified using NIH Image J software. Activation levels were
determined as the ratios of phosphoprotein to the total
protein or loading controls.
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The effects of AnxA6 depletion and TKIs on cell growth
were performed in 24-well plates in triplicates using 1 x 104
cells/well, as previously described [5]. The proliferation and
viability of the cells were determined by incubating the cells
in 1:10 diluted PrestoBlue reagent (Invitrogen) in HBSS
supplemented with 1 mM Ca2+ and 0.5 mM Mg2+ for 2–
4 h. Cell proliferation was determined by fluorescence
measurement following excitation at 540 nm and emission
at 600 nm.
Growth in 3D cultures and motility assays
Clonogenic and motility assays were performed in duplicate
as previously described [5]. Digital images of the 3D cul-
tures were captured at x10 magnification using DCM200
digital camera and Scopephoto software. For motility as-
says, cells were counted from at least 5 separate fields per
insert.
In silico analyses
The online KM plotter was used to compare the impact of
AnxA6 expression on the survival of 2,977 breast cancer
patients according to the set parameters [36]. In order to
analyze the prognostic value of a particular gene, the co-
horts are divided into two groups according to the median
(or upper/lower quartile) expression of the gene. A survival
curve is displayed, and the hazard ratio with 95% confi-
dence intervals and logrank P value are calculated and dis-
played [36]. We tested the effect of high or low AnxA6
expression on the overall, distant metastasis-free and
recurrence-free survival of either all patients or patients
with various breast cancer molecular subtypes.
Statistical analysis
Data were analyzed using Microsoft Excel 2007. Ex-
cept otherwise indicated data were presented as mean
± SD. Data were analyzed using Student’s t-test; a
p-value < 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1. Down regulation of AnxA6 in BT-549 and
MDA-MB-231 breast cancer cells. (A) BT-549 and MDA-MB-231 cell lines
were transfected with shRNAs in pGIPZ and cloned as described in “Mate-
rials and methods”. Whole cell lysates from the isolated clones generated
from two distinct shRNAs designated A6sh2 and A6sh5 were analyzed by
Western blotting. Densitometric analysis of the expression of AnxA6 ex-
pression relative to GAPDH is presented. B) Whole cell lysates from the
selected clones were analyzed by western blotting using antibodies
against AnxA6, EGFR and GAPDH.
Additional file 2: Figure S2. Differential expression of AnxA6 and EGF-
induced activation of EGFR in normal breast epithelial and breast cancer
cells A) mRNA levels of AnxA6 and EGFR in normal breast epithelial and
breast cancer cells. Equal amounts (1 μg) of total RNA extracted from the
indicated cell lines were used for the first strand synthesis and quantita-
tive PCR was programmed with 10% of the first strand reactions. Bars rep-
resent gene expression levels normalized to GAPDH ± s.d. from threeindependent determinations. (B) AnxA6 expression and EGF-induced acti-
vation of EGFR and downstream signaling in normal and breast carcin-
oma cell lines. The indicated cell lines were grown to 70% confluency,
followed by serum starvation for 24 h. Cells were then treated with EGF
for 0–90 min and harvested by scrapping in ice-cold PBS. Equal amounts
of whole cell lysates were separated in 4-12% polyacrylamide gels under
reducing conditions and analyzed by Western blotting using the indi-
cated antibodies.
Additional file 3: Figure S3. Over-expression of AnxA6 in HCC1806
enhances the expression of EGFR but inhibits receptor activation and
anchorage-independent growth. (A) Control (HCC1806-EV) and AnxA6
over-expressing HCC1806 (HCC1806-AnxA6) cells were grown to 70%
confluency and serum-starved for 24 h. Cells were then treated with EGF
for 0–90 min, and whole cell lysates were analyzed by western blotting
using the indicated antibodies. End.AnxA6 = endogenous AnxA6 (B)
Densitometric analysis of AnxA6 and EGFR protein expression. Expression
levels in control and AnxA6 over-expressing HCC1806 cells were normal-
ized to GAPDH. Bars represent AnxA6 or EGFR protein expression ± s.d.
from three independent experiments relative to the levels in control cells.
(C) Densitometric analysis of activated EGFR. Points represent phospho-
EGFR remaining at the indicated times from a representative experiment.
(D) Densitometric analysis of activated ERK1/2. Points represent phospho-
ERK1/2 levels at the indicated times from a representative experiment. (E)
3D Matrigel growth assays. Control and AnxA6 over-expressing HCC1806
cells (5 × 103 cells/assay) were cultured in 3D matrigel cultures for up to
10 days. Digital images of the colonies were captured with a digital cam-
era (x10 magnification).
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